Thus, we considered recommendations of ASCO (American Society of Clinical Oncology), ESMO (European Society for Medical Oncology) and Turkish Oncology Society and we continued providing anticancer therapy by preferring the regimens causing less neutropenia risk and administering G-CSF when required in ECOG-PS 0–1 patients with good general conditions. Here, CSF3 is linked to Decreased total neutrophil count.